No Data
No Data
"Interest rate cuts + Trump's return" two major expectations continue to ferment! Will this benefiting sector see the dawn?
Market participants believe that in recent three years, the biotechnology sector has been underperforming the broader market. Once the expectation of interest rate cuts is raised by the Fed, biotechnology companies, represented by innovative drugs, will have the ability to make up ground.
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
After the first televised debate for the US presidential election, the first wave of market reactions has arrived!
According to Goldman Sachs, the overall market activity on Friday experienced an explosive growth. Although US inflation cooled down in May, the long-term US Treasury yields reversed the early decline and soared at the close. Barclays recommends buying inflation-protected assets in preparation for Trump's victory.
Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2024 Results on July 17, 2024
Elevance Health (NYSE:ELV) will release second quarter 2024 financial results on July 17, 2024, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call
Investing in Elevance Health (NYSE:ELV) Five Years Ago Would Have Delivered You a 103% Gain
Elevance Health Insiders Sell US$9.2m Of Stock, Possibly Signalling Caution
The fact that multiple Elevance Health, Inc. (NYSE:ELV) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. Knowing whether insid